BTK and head and neck squamous cell carcinoma: Altogether, the here presented data suggest that targeting BTK activity could be a promising therapeutic option for HNSCC patients, either as monotherapy or possibly in combination with current treatment options like target therapy, radiotherapy or immune checkpoint inhibition.